| abstract |
The present invention relates to the use of a compound of formula I as an inhibitor of phosphodiesterase type 10A and its salts and the like, thereby treating or modulating a medical disorder selected from neurological and psychotic disorders and alleviating the symptoms associated with said disorders And to their use for the manufacture of medicaments suitable for reducing the risk of these disorders. Formula I In the above formula (I) Y 1 and Y 2 are adjacent atoms in Het 1 , which is independently selected from the group consisting of carbon and nitrogen; k is 0, 1, 2 or 3; Het 1 is a divalent monocyclic 5 or 6 membered heteroaromatic radical having as ring members 1, 2 or 3 heteroatoms or heteroatom moieties selected from O, S, N and NR a , or O, S, 9 or 10 membered heteroaromatic radical having 1, 2, 3 or 4 heteroatoms or heteroatom moieties selected from N and NR a as ring members; Het 2 is a monocyclic 5 or 6 membered heteroaryl having as ring members 1, 2 or 3 heteroatoms or heteroatom moieties, in particular selected from O, S, N and NR 1a ; Cyc is in particular an optionally substituted monocyclic 5-membered or 6-membered heteroaryl or optionally substituted fused 8-membered, 9-membered or 10-membered bicyclic hetaryl; Ar is optionally substituted phenylene or optionally substituted divalent 6-membered heteroaryl; R is attached to a carbon atom of Het 1, R is in particular halogen, C 1 -C 6 - alkyl, C 2 -C 6 - alkenyl, C 2 -C 6 - alkynyl, C 1 -C 6 - alkoxy , C 1 -C 6 -fluoroalkyl, C 1 -C 6 -fluoroalkoxy, C 3 -C 6 -cycloalkyl, and the like. |